intrathecal bupivacaine with epinephrine

PreclinicalSmall molecule

intrathecal bupivacaine with epinephrine is one of 5 small molecule programs targeting Total Knee Replacement. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Total Knee ReplacementCompleted

Total Knee ReplacementPreclinical

Completed

Competition

Competitive Landscape

5 competitors in Total Knee Replacement

#DrugCompanyPhaseTrials

Bupivacaine Liposome

Pacira Pharmaceuticals, Inc

Phase 3

1 2

Medrol

Pfizer

Preclinical

1 3

Bupivacaine-Liposomal Bupivacaine

YYale University

Phase 2

2 4

EVICEL

MMontefiore Medical Center

Preclinical

1 5

intrathecal bupivacaine with epinephrine

SSeoul Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Total Knee Replacement1 trial

ED50 and ED95 of Intrathecal Bupivacaine With or Without Epinephrine for Total Knee Replacement Arthroplasty

Completed·SSeoul Medical Center·N/A·NCT01264575·162 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for intrathecal bupivacaine with epinephrine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intrathecal bupivacaine with epinephrine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intrathecal bupivacaine with epinephrine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSeoul Medical Center

intrathecal bupivacaine with epinephrine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Total Knee Replacement1 trial

References

Drug Info

Quick Facts

Related News